Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IBI310, Bevacizumab Combined With Sintilimab in First-line Treatment of Advanced Hepatocellular Carcinoma
NCT05363722Phase 1Unknown
- Sponsor
- Zhongshan Hospital, Fudan University
- Start
- May 2022
- Primary completion
- Apr 2023
- Modality
- Monoclonal Antibodies
01
Overview
Phase 1, randomised, open-label trial of IBI310 in hepatocellular carcinoma (HCC) (2 arms), sponsored by Zhongshan Hospital, Fudan University. Primary endpoint: Objective Response Rate at 3 years. Status: unknown.
02
Drugs
IBI310
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT05363722.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05363722.